Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3938577 · 3 trials · 4 indications
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
PK: AUC of LY3938577 for intravenous administration
PK: AUC of LY3938577
PK: AUC of LY3938577 for SC administration
PK: AUC of LY3938577 for SC administration
PK: Cmax of LY3938577
PK: Cmax of LY3938577
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY3938577 | EXPERIMENTAL | Participants will receive LY3938577 subcutaneously (SC) |
| Degludec | ACTIVE_COMPARATOR | Participants will receive degludec SC |
| Part A Period 1: LY3938577 | EXPERIMENTAL | Single dose of LY3938577 administered intravenously (IV) in healthy participants. |
| Part A Period 1: Placebo | PLACEBO_COMPARATOR | Single dose of Placebo administered intravenously (IV) in healthy participants. |
| Part B: LY3938577 | EXPERIMENTAL | For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of LY3938577 administered intravenously with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level. |
| Part B: Insulin Degludec | ACTIVE_COMPARATOR | For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of Insulin Degludec administered intravenously with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level. |
| Part C: LY3938577 | EXPERIMENTAL | LY3938577 administered subcutaneously (SC) |
| Part C: Insulin Degludec | ACTIVE_COMPARATOR | Insulin Degludec administered subcutaneously (SC) |
| Part A Period 2: LY3938577 | EXPERIMENTAL | Sequential dose of LY3938577 administered subcutaneously (SC). |
| Part A Period 2: Placebo | PLACEBO_COMPARATOR | Sequential dose of Placebo administered subcutaneously (SC) |
| Part D Period 1: Basal Insulin and Lispro Prandial Insulin | OTHER | Pre-study basal insulin (provided by patient) and lispro prandial insulin administered SC |
| Part D Period 2: Lispro Prandial Insulin and LY3938577 | EXPERIMENTAL | Lispro prandial insulin and LY3938577 administered SC |
| LY3938577 (Part A) | EXPERIMENTAL | LY3938577 administered Subcutaneously (SC). |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Insulin degludec (Part A) | ACTIVE_COMPARATOR | Insulin degludec administered SC. |
| LY3938577 (Part B) | EXPERIMENTAL | LY3938577 administered SC. |
| Insulin degludec (Part B) | ACTIVE_COMPARATOR | Insulin degludec administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3938577 | DRUG | Administered SC |
| Degludec | DRUG | Administered SC |
| Placebo | DRUG | Administered Intravenously (IV) |
| Insulin Degludec | DRUG | Administered Intravenously (IV) |
| Insulin Lispro | DRUG | Administered Intravenously (IV) |
| Basal Insulin | DRUG | Administered subcutaneously (SC) |
| Lispro Prandial Insulin | DRUG | Administered subcutaneously (SC) |
Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)...
LY3938577 is an investigational small molecule being studied for metabolic conditions, including Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, as well as in healthy participants. It is being developed by Eli Lilly and Company and is currently in Phase 2 clinical development.
LY3938577 is a small molecule being developed by Eli Lilly and Company for metabolic diseases. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its effects on glucose control in patients with diabetes.
LY3938577 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is an investigational small molecule in clinical development for metabolic conditions.
LY3938577 is currently in Phase 2 clinical development. It has completed a Phase 1 study in healthy participants and those with Type 2 Diabetes Mellitus, and an additional Phase 1 study is recruiting participants. The drug is not yet approved and remains investigational.
LY3938577 has been studied in three clinical trials. NCT06132126, a completed Phase 1 study in healthy participants and those with Type 2 Diabetes, enrolled 66 participants. NCT06280703, a recruiting Phase 1 study in healthy participants and those with Type 1 Diabetes, aims to enroll 118. NCT07215312, an active Phase 2 study in Type 2 Diabetes patients previously treated with basal insulin, targets 100 participants.
No alternative names for LY3938577 have been reported. The drug is identified solely by its code name LY3938577 in clinical trial registrations and is being developed by Eli Lilly and Company for metabolic conditions.